About
Suven Pharmaceuticals Ltd
Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.
During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.
In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.
The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.
The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.
During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.
As on 31 March 2020,the company has one subsidiary and one associate company under its roof.
The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.
The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..
In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.
During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
Suven Pharmaceuticals Ltd
Chairman Speech
Dear Shareholders,
With immense satisfaction yet a heavy heart, I ink my last message as
Managing Director of Suven Pharmaceutical Limited. We have sold our stake in the Company
to Advent International, one of the world's largest and most experienced private equity
investors.
I want to take the opportunity to address two questions that may be
spawning in your mind.
Why did we sell the stake in the Company? The answer is simple. To
ensure that Suven Pharma sustains its commitment to create enormous value for its
shareholders. Let me elucidate the thought.
Over the years, we carefully grew our CRAMS business as a part of Suven
Lifesciences Limited from a small venture into a globally respected enterprise supporting
large companies in their innovation projects. More recently, we spun off the CRAMS
business into Suven Pharmaceutical, a strategy that created significant value for our
shareholders.
Now Suven Pharmaceutical is a large and globally respected company. To
sustain the Company's growth momentum and wealth creation capability, we need to
ideate and identify new opportunities that allow us to utilise our core strengths better
and will emerge as new growth levers for Suven Pharma. Our divestment has allowed us to
bring in new partners who will help in achieving this strategic vision which will
significantly enhance the value proposition for stakeholders over the medium term.
Why Advent International? They come in with multi-decadal experience in
efficiently managing global-scale enterprises. Other interested investors had also
approached us for acquiring the Company, but what tilted the scale in their favour was our
shared and aligned vision for Suven Pharma - to graduate the Company into a new orbit of
growth and respect with global innovators.
It gives me considerable peace of mind that Suven Pharma, which we had
so carefully fostered in the crucible of passion and perseverance, is in the right hands
and will be taken forward to greater heights by a like-minded management team.
The new management has the depth of knowledge and the bandwidth of
expertise and experience to navigate the Company through the current headwinds and
capitalise on growth opportunities over the medium term to deliver immense value to all
stakeholders.
The medium-term
The passion and pace of innovation projects, especially in the Western
world, are closely dovetailed with economic progress owing to the immense resources
deployed. Given the highly turbulent geopolitical situation, economic progress across
nations in the current year will be impacted, directly or otherwise. This will decelerate
the momentum of ongoing research projects and postpone initiating new projects.
As the vigor of human conflicts diminishes and the world order
gravitates towards a more balanced position, innovation intensity will only accelerate.
Moreover, the innovation world is moving East owing to the incredible value-proposition
provided by the East, especially India.
The opportunities for India, in my opinion, should expand, considering
that global innovators are seriously considering a credible alternative to China for
supporting them in their innovation journey. While the shift will take time, as there are
a plethora of considerations and regulatory challenges in orchestrating a shift between
nations and enterprises, I am confident that some relocation will happen over the next 3-4
years.
Suven Pharma is perfectly poised for a brighter tomorrow. We have
invested in relevant technologies and capabilities to effectively and efficiently secure
opportunities and sustain our success.
As I leave my office with truckloads of successes, experiences,
learnings and memories, I look forward to reading about the Company's achievements over
the coming years. I wish the new management well and will continue to support them as an
advisor for some time.
In closing, I take this opportunity to thank my colleagues on the Board
for their continued support in drawing the long-term blueprint for the Company. I thank
the Management team for building relevant strategies and executing them flawlessly. I
thank the entire Suven Pharma team for their unwavering support in building the
organization to where it is now – without their untiring efforts; we would never have
made it this far. I also express my sincere gratitude to all other stakeholders for your
continuing support. I am sure you will continue supporting the new management in the same
manner you backed me.
Warm regards,
Venkat Jasti
Managing Director
  Â
Suven Pharmaceuticals Ltd
Company History
Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors. Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.
During the year 2019-20, Suven Life Sciences Ltd. (SLSL) has transferred the CRAMS business undertaking to the Company in accordance with the Scheme of Arrangement (Demerger) approved by the Hon'ble NCLT, Hyderabad Bench now integrated with Contract Development and Manufacturing Operations (CDMO) business model of the Company.
In terms of the sanctioned Scheme, the Company issued and allotted 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each of SPL for every 1 (One) fully paid up equity share of face value of Re 1/- (Rupee One only) each held by each shareholder in the Demerged Company (SLSL) as on the Record Date (i.e., 22nd January, 2020), thereby resulted in a mirror shareholding of SLSL in the Company. The equity shares of the Company were listed to trade w.e.f. 09th March, 2020.
The Board of Directors in its meeting held on August 17, 2020 considered, approved and recommended an issue of bonus shares in the proportion of (1:1) one new equity share of the Company of Re 1 each for every one existing equity share of the Company of Re 1 each.
The company has a massive Rs 320-crore capex plan. Suven has invested Rs 120 crore in 2019-20. The balance is to be invested in 2020-21.
During the year 2019-20, the Company invested USD35 million in Rising Pharma Holdings, Inc., USA through its wholly owned subsidiary, Suven Pharma, Inc., USA. Suven Pharma, Inc., in USA was originally formed by Suven Life Sciences Ltd while pursuing various business opportunities in CRAMS business undertaking during the demerger transition period now integrated with CDMO business of the Company, as per the decisions taken by the Board of the Company and of the Demerged Company i.e., Suven Life Sciences Ltd, in accordance with the enabling provisions of Scheme of Arrangement as sanctioned by Hon'ble NCLT Hyderabad Bench. As a result, Suven Pharma, Inc., in USA has become wholly owned subsidiary of the company during the FY 2019-2020.
As on 31 March 2020,the company has one subsidiary and one associate company under its roof.
The company filed 11 ANDAs as on March 31, 2020 and three of those secured the green light from the regulator.
The Board has allotted the Bonus shares at 1:1 ratio in its Board Meeting held on 29 September 2020. Accordingly the number of shares increased from 12,72,82,478 to 25,45,64,956..
In 2022, the Company filed 17 ANDAs of which 9 had received approvals and 8 products were launched up to March, 2022.
During year 2022, Company acquired 100% stake in Casper Pharma Private Limited, a Hyderabad based SEZ unit and Casper Pharma became a Wholly Owned Subsidiary of the company.
Suven Pharmaceuticals Ltd
Directors Reports
Suven Pharmaceuticals Ltd
Company Background
| Incorporation Year | 2018 |
| Registered Office | 8-2-334 SDE Serene Chambers,3 Floor Avenue 7 Road No 5
Hyderabad,Telangana-500034 |
| Telephone | 91-40-23549414/1142/3311,Managing Director |
| Fax | 91-40-23541152 |
Annaswamy VaidheeshVenkatanaga Kali Vara Prasad Raju Vetukuri| Company Secretary | Hanumantha Rao Kokkonda |
| Auditor | Karvy & Co |
| Face Value | 1 |
| Market Lot | 1 |
| Listing | BSE,NSE, |
| Registrar | KFin Techologies Ltd
Karvy Selenium Tow-B,31&32 Financial Dist,Nanakramguda ,Hyderabad-500032 |
Suven Pharmaceuticals Ltd
Company Management
| Director Name | Director Designation | Year |
|---|
| Hanumantha Rao Kokkonda | Company Sec. & Compli. Officer | 2023 |
| Shweta Jalan | Non Executive Director | 2023 |
| U B Pravin Rao | Independent Director | 2023 |
| Annaswamy Vaidheesh | Executive Chairman | 2023 |
| Venkatanaga Kali Vara Prasad Raju Vetukuri | Managing Director | 2023 |
| Pankaj Patwari | Non Executive Director | 2023 |
| Matangi Gowrishankar | Independent Director | 2023 |
| Vinod Rao | Independent Director | 2023 |
| K G Ananthakrishnan | Independent Director | 2023 |
Suven Pharmaceuticals Ltd
Listing Information
| Listing Information |
|---|
| BSE_500 |
| BSE_HC |
| CNX500 |
| BSESMALLCA |
| BSEALLCAP |
| SML250 |
| MSL400 |
| NFTYMSC400 |
| NFTYSC250 |
| NF500M5025 |
| NFTYTOTMKT |
| NFTYMIDSMH |
| NMIM503020 |
Suven Pharmaceuticals Ltd
Finished Product
| Product Name | Unit | Installed
Capacity | Production
Quantity | Sales
Quantity | Sales
Value |
|---|
| Sale of Products | NA | 0 | 0 | 0 | 773.5708 |
| Sale of Services | NA | 0 | 0 | 0 | 43.7053 |
| Export Incentives | NA | 0 | 0 | 0 | 13.0821 |
| Duty Drawback | NA | 0 | 0 | 0 | 3.4241 |
| Other Operating Income | NA | 0 | 0 | 0 | 0.0075 |
| Service tax rebate claim recvd | NA | 0 | 0 | 0 | 0 |